Monaco Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Monaco Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43,966	Closed	-$1.14M	–	101
2025 Q2	$1.14M	Sell	43,966 -27,294	-38%	-$306K	0.2%	60
2025 Q1	$727K	Sell	71,260 -64,265	-47%	-$840K	0.15%	58
2024 Q4	$1.89M	Buy	135,525 +2,377	+2%	+$41.9K	0.27%	43
2024 Q3	$2.6M	Sell	133,148 -11,281	-8%	-$215K	0.38%	44
2024 Q2	$2.69M	Sell	144,429 -244,342	-63%	-$5.15M	0.43%	28
2024 Q1	$5.45M	Sell	388,771 -9,455	-2%	-$99K	1.63%	18
2023 Q4	$3.37M	Buy	398,226 +77,586	+24%	+$588K	0.99%	32
2023 Q3	$2.86M	Sell	320,640 -296,741	-48%	-$2.86M	0.85%	29
2023 Q2	$5.33M	Buy	+617,381	New	+$6.58M	1.49%	18
2020 Q1	–	Sell	-10,333	Closed	-$3.35M	–	70
2019 Q4	$3.35M	Buy	+10,333	New	+$3M	1.5%	22

Other funds holding NKTR

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Monaco Asset Management's NKTR Position: Q3 2025 in Review

Monaco Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2025, closing a stake of 43,966 shares — an estimated $1.14M sold.

Monaco Asset Management first reported a position in NKTR in Q4 2019 and held it in 10 quarters. The position peaked at $5.45M in Q1 2024. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

Monaco Asset Management reported no remaining Nektar Therapeutics position as of Q3 2025 after selling out during the quarter.
Monaco Asset Management sold 43,966 Nektar Therapeutics shares in Q3 2025, an estimated $1.14M.
Monaco Asset Management first reported a position in Nektar Therapeutics in Q4 2019 and held it in 10 quarters.
Monaco Asset Management's Nektar Therapeutics position peaked at $5.45M in Q1 2024.
154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Monaco Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.